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ABSTRACT 
Ductile and low melting point drugs exhibit challenging behaviour during both 
particle size reduction and spray drying as considerable amount of heat is involved 
in both processes. In this study, a systematic approach was employed to 
understand the preparation and in-vitro performance of respirable nanoparticle 
agglomerates by coupling wet milling and spray drying for ibuprofen, which is a 
drug with a low melting point and challenging mechanical properties. Wet milling 
in the presence of two stabilizers differing in their thermal properties and 
subsequent spray drying of the suspensions were employed after the addition of 
mannitol and/or leucine. The effects of the stabilizer type and the amounts of 
mannitol (matrix former) and leucine (dispersibility enhancer), on the yield of the 
process, the particle size, the redispersibility (i.e. reformation of nanoparticles 
upon rehydration) and the aerosolization (fine particle fraction, FPF%) of the 
nanoparticle agglomerates were evaluated using standard least squares model and 
a 23 full factorial design (3 factors at 2 levels plus four centre points). All factors 
investigated were found to have a significant effect on the yield of nanoparticle 
agglomerates (p<0.05). The size of the nanoparticle agglomerates was mainly 
dependent on the leucine to drug ratio and the type of stabilizer (p<0.05), while 
mannitol to drug ratio was the only significant factor affecting the redispersibility 
of the formulations (p<0.05). The FPF%, determined using a fast screening 
impactor, was found to be dependent on both the leucine and mannitol to drug 
ratio (p<0.05). This study demonstrates the successful preparation of respirable 
nanoparticle agglomerates of low melting point and ductile ibuprofen and the 
usefulness of the design of experiments as a tool to understand the impact of the 
formulation parameters on their fabrication and in-vitro performance.  
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1. Introduction 1 
 2 
Nanocrystals are nanosized drug particles. Nanocrystals are typically produced in 3 
the form of nanosuspensions, which are submicron, colloidal dispersions of 4 
nanosized drug particles, stabilised by surfactants, polymers, or a mixture of both  5 
[1]. Nanocrystals have been suggested as a beneficial formulation approach for 6 
Class IIa drugs of the Biopharmaceutics Classification System (BCS), for which 7 
the dissolution rate is the rate-limiting step of absorption [2]. Considering the 8 
various nanosizing techniques (i.e. top-down and bottom-up), wet milling is a 9 
reproducible, cost-effective and scalable way of preparing nanosuspensions with 10 
a typical size ranging from 200-500 nm [3]. Wet milling is the technique for the 11 
preparation of the majority of the nanosuspension-based pharmaceutical 12 
formulations that are either on the market or currently under development [4,5].  13 
 14 
Solidification of the nanosuspensions has been explored to combine the 15 
advantages of liquid nanosuspensions (i.e. enhanced dissolution and solubility) 16 
with the benefits of solid formulations (i.e. stability, easier handling, enhanced 17 
patient compliance) producing nanoparticle agglomerates suitable for oral and 18 
pulmonary delivery. Spray drying is a single-step process for the conversion of a 19 
liquid feed into a dried particulate form. It is a popular process from an industrial 20 
perspective as it is more cost- and time-effective compared to freeze drying [6]. 21 
Therefore, preparation of nanosuspensions by wet milling followed by 22 
solidification, using spray drying, has been suggested as a formulation approach 23 
for nanoparticle agglomerates with enhanced dissolution and aerosolization 24 
efficiency [7–10].   25 
 26 
Spray drying is also a fundamental particle engineering technique for pulmonary 27 
drug delivery due to its simplicity, adaptability and scalability. Spray drying is a 28 
rapid solidification procedure and the obtained particles (at least from solution 29 
feed) are usually amorphous. Amorphicity is regarded as a disadvantage for 30 
respirable particles as it is associated with the danger of recrystallisation upon 31 
storage, which may influence adversely the stability, dissolution, absorption and 32 
aerosolisation efficiency of the product [11]. Moreover, during spray drying 33 
nanocrystals are exposed to thermal stresses, which may cause irreversible 34 
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aggregation to the resultant formulations [12]. Irreversible aggregation is linked 35 
with poor redispersibility of the nanoparticle agglomerates, which cannot reform 36 
nanoparticles upon rehydration leading to the loss of the advantages of the 37 
nanoformulations [12,13].  38 
 39 
Addition of generally recognised as safe (GRAS) excipients in the liquid feed 40 
before spray drying is a common strategy to manipulate the properties and thus the 41 
performance of the dry powders. Mannitol is a non-reducing sugar, which has been 42 
approved by regulatory authorities for use in inhalable pharmaceutical products 43 
[14]. In particular, mannitol exhibits excellent spray-drying properties as the size 44 
and morphology of the particles can be modified by varying the process parameters 45 
[15]. The crystallinity of the spray-dried mannitol and the non-hygroscopic nature 46 
of this excipient are advantageous for the long-term stability of the dry powders 47 
[16]. Moreover, mannitol has been used as a matrix former during the 48 
solidification of nanosuspensions [7,10,17–19]. As a water-soluble compound, 49 
mannitol forms a matrix around the nanoparticles, which upon rehydration 50 
dissolves allowing the reformation of the primary nanoparticles.  51 
 52 
Leucine is an endogenous amino acid, which exhibits aerosolization-enhancing 53 
properties [14,16]. Leucine was found to influence particle formation and to 54 
reduce the cohesiveness of spray-dried mannitol particles, which subsequently 55 
resulted in higher emitted fractions [20,21]. According to Sou et al. [20], “it is a 56 
combination of a high surface activity during the drying process, mass transport 57 
within the droplet, followed by subsequent self-assembly packing on the particle 58 
surface which may explain the dispersibility enhancing effect of leucine”. 59 
Modification of particle morphology in response to higher concentrations of 60 
leucine has been previously reported [20,22]. More specifically, when leucine was 61 
co-spray dried with mannitol and trehalose it was found that a leucine 62 
concentration <5% w/w was insufficient for discrete particle formation, a 63 
concentration of 5-20% w/w resulted in reduced particle aggregation while a 64 
concentration >20% w/w led to increased surface corrugation [21].  According to 65 
Mangal et al. [23], the surface concentration of leucine governs particle formation 66 
and optimum surface concentration of this amino acid results in optimum surface 67 
and bulk properties of the spray-dried powders.  68 
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Ibuprofen was selected as a poorly water-soluble model drug with a low melting 69 
point (75-78 oC) and challenging mechanical properties as it exhibits a high brittle-70 
ductile transition point of 854 μm [24]. Below this point, it is hard to reduce the 71 
size of particles by dry milling, as the particles tend to deform rather than fragment. 72 
Despite the high ductility of ibuprofen, it was reported that wet milling using a 73 
Micros Ring Mill resulted in particles with a diameter about 8-11 μm (much 74 
smaller than the critical diameter of 854 μm) [25]. The superior size reduction 75 
performance of wet milling was attributed to the contribution of shear forces, 76 
which cause ductile fracture of crystals. Besides the ductility of ibuprofen, its low 77 
melting point poses additional challenges to conventional nano-comminution 78 
techniques. The heat generated in the mill may result in partial melting of the drug 79 
particles and thereby formation of large aggregates or drug amorphisation [26–80 
28]. In a recent study by Lestari et al. [29], ibuprofen was classified as a drug with 81 
poor millability as high concentrations of stabilizers and extended milling times 82 
were required to produce stable nanosuspensions by wet milling.  83 
 84 
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) for treating fever, 85 
pain and inflammation; it was recently reported that ibuprofen acts synergistically 86 
with antibiotics and thus might play a multifunctional role in the treatment of 87 
cystic fibrosis infections [30]. Based on this new evidence, Yazdi et al. [31] 88 
formulated carrier-free dry powder inhalations of micronized (jet-milled) 89 
ibuprofen as an attractive alternative to oral administration of the drug in cystic 90 
fibrosis. Therefore, preparation of respirable nanoparticle agglomerates of 91 
ibuprofen with increased dissolution may be used as an alternative formulation 92 
approach for the targeted delivery of ibuprofen to the lungs.  93 
 94 
In this study, wet milling of ibuprofen using two different stabilizers, namely 95 
hypromellose (HPMC) and D-α-tocopherol polyethylene glycol 1000 succinate 96 
(TPGS), followed by spray drying, after the addition of excipients, was assessed. 97 
Different grades of HPMCs have been found to be the most effective stabilizers 98 
in terms of particle size reduction and short-term physical stability of ibuprofen 99 
nanosuspensions [32] while TPGS due to its low viscosity and high surface 100 
activity has been identified as the surface modifier with the highest success rate 101 
on stabilizing nanosuspensions of various drugs [33]. These two stabilizers differ 102 
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with respect to their thermal properties; HPMC has a glass transition temperature 103 
of 125.5 oC [34] while TPGS is a thermosensitive surfactant with low melting 104 
point (m.p. 38 oC). The effect of these two stabilizers on the size reduction of 105 
nanosuspensions was investigated. The solid state, particle morphology and the 106 
dissolution profiles of the spray-dried nanoparticle agglomerates were also 107 
assessed. A full factorial design and standard least squares model were employed 108 
to understand the critical formulation parameters as well as any interactions 109 
between them involved in the wet milling and spray drying process and finally in 110 
the formation of respirable nanoparticle agglomerates. The critical formulation 111 
parameters investigated were: type of stabilizer, mannitol to drug ratio and leucine 112 
to drug ratio. The yield of the process, the particle size distribution, the 113 
redispersibility and the fine particle fraction were investigated as responses. To 114 
the best of our knowledge, it is the first time that such a study is carried out 115 
focusing on respirable nanoparticle agglomerates of a low melting drug. 116 
 117 
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2. Materials and methods 118 
 119 
2.1. Materials 120 
Ibuprofen (IBU, Shasun Pharmaceuticals, India) with volume mean diameter D4,3: 121 
64.5 ± 8.3 μm was used. Pharmacoat 603 (low viscosity hypromellose, HMPC 122 
2910, Shin-Etsu Chemical Co., Japan) and D-α-tocopherol polyethylene glycol 123 
1000 succinate (TPGS, Sigma Aldrich, USA) were used as stabilizers. Mannitol 124 
(Pearlitol® 160C, Roquette Frères, Lestrem, France) and L-leucine (Sigma 125 
Aldrich, USA) were used as a matrix former and a dispersibility enhancer of the 126 
nanoparticle agglomerates, respectively. HycloneTM Water for Injections (Thermo 127 
Scientific, UK) was used for the preparation of nanosuspensions. Methanol and 128 
acetonitrile were HPLC grade and all other reagents were of analytical grade.  129 
 130 
2.2. Methods 131 
2.2.1. Preparation of nanosuspensions 132 
Nanosuspensions were prepared by wet bead milling using a laboratory planetary 133 
mill (Pulverisette 5, Fritsch Co., Germany). 0.5 g IBU, the stabilizer (10% w/w of 134 
IBU) and 10 g of milling beads (0.5 mm diameter aluminium borosilicate glass 135 
grinding beads, Gerhardt, UK) were weighed into each glass vial of 14 mL 136 
capacity and suspended in 10 mL Water for Injections. The vials were placed into 137 
a stainless steel milling pot with a maximum loading capacity of 8 vials. Rotation 138 
speed (200 rpm), milling duration (6 cycles) and stabilizer concentration (10% 139 
w/w of IBU) were selected based on preliminary studies. Each milling cycle 140 
comprised 30 min rotation followed by 20 min pause. At each pause, the 141 
nanocrystal size was determined and at the end of the milling procedure, the 142 
nanosuspensions were allowed to cool to room temperature and collected by 143 
withdrawal using a pipette for separation from the milling beads. 144 
2.2.2. Particle size distribution of nanosuspensions 145 
Malvern Nano ZS (Malvern Instrument, UK) was used for size measurements by 146 
dynamic light scattering (DLS) yielding the intensity-weighted mean 147 
hydrodynamic diameter of the bulk population (z-average) and the polydispersity 148 
index (PI) as a measure of the width of size distribution. 20 μL of nanosuspension 149 
was diluted with 10 mL of saturated IBU solution, prepared by filtration of a 150 
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suspension through a 0.1 μm disposable syringe filter to avoid extensive 151 
dissolution and was then shaken vigorously for 30 s by hand before being 152 
transferred to disposable sizing cuvettes. The measuring parameters were: 153 
dispersant refractive index of 1.338 and viscosity of dispersion medium 0.89 cP. 154 
All measurements were performed in triplicate. 155 
2.2.3. Preparation of nanoparticle agglomerates 156 
The obtained nanosuspensions were solidified by spray drying immediately after 157 
preparation. 10 mL of nanosuspension were diluted to 100 mL with an aqueous 158 
solution of mannitol and/or leucine to obtain the proportions reported in Table 1. 159 
Spray drying was performed using a laboratory scale spray dryer (Mini B-290, 160 
Buchi Labortechnik, Switzerland) fitted with a high performance cyclone. On the 161 
basis of preliminary experiments, the following parameters were employed: inlet 162 
temperature of 70 o C, outlet temperature of 50 ± 2 o C, feed rate of 5 mL min-1 and 163 
atomizing gas flow rate of 0.5 L s-1. The collected nanoparticle agglomerates were 164 
weighed and stored in a desiccator over silica gel for subsequent testing. 165 
2.2.4. Determination of yield  166 
Yield was calculated as the ratio of the mass of the particles collected after spray 167 
drying to the mass of solids (drug and excipients) introduced in the feed suspension. 168 
The drug quantity used in the calculations was the amount weighed in the milling 169 
pots before the wet-milling step. 170 
 171 
2.2.5. Characterization of nanoparticle agglomerates 172 
2.2.5.1. Particle size analysis 173 
Particle size distributions of the nanoparticle agglomerates were determined by 174 
laser diffraction using a HELOS/ BR laser diffractometer (Sympatec, Germany) 175 
which was fitted with the micro-dosing unit ASPIROS and the dry disperser 176 
RODOS. Samples were placed in the feeder and pressurized air at 4 bar was used 177 
to disperse them in the measurement chamber, while the feeding velocity was kept 178 
constant at 50 mm s-1. An R2 lens detector (0.25- 87.5 μm) and the particle size 179 
distribution analysis software Windox 5 (Sympatec, Germany) were used. The 180 
D10, D50 and D90 particle sizes (i.e. the size in microns at which 10%, 50% and 181 
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90% of the particles are smaller) were recorded. Measurements were carried out 182 
in triplicate. 183 
 184 
2.2.5.2. Scanning electron microscopy 185 
The morphology of the starting materials and the nanoparticle agglomerates was 186 
investigated using scanning electron microscopy (SEM). Samples were placed on 187 
to double-sided electro-conductive adhesive tape, which was fixed onto an 188 
aluminium stub and then sputter-coated with gold (10 nm thickness). SEM 189 
micrographs were taken using a FEI Quanta 200 FEG ESEM (FEI, Netherlands), 190 
at 5.00 kV. 191 
 192 
2.2.5.3. X-ray powder diffraction 193 
X-ray powder diffraction (XRPD) was employed to assess the crystallinity of the 194 
starting materials and the nanoparticle agglomerates. XRPD patterns were 195 
obtained with a bench-top diffractometer (Rigaku Miniflex 600, Japan). Cu Kα 196 
radiation at 15 mA and 40 kV with a step of 0.02 deg and a speed of 5 deg min-1 197 
was used, covering a 2 θ of 5-40 o. Miniflex Guidance (Rigaku, Japan) was the 198 
analysis software.  199 
2.2.5.4. Differential scanning calorimetry  200 
Differential scanning calorimetry (DSC) was performed using a TA DSC Q200 201 
calorimeter (TA Instruments, USA) previously calibrated with indium. Accurately 202 
weighed powder samples (1-3 mg) were sealed into crimped standard aluminium 203 
pans (TA) and heated under nitrogen flow (50 mL min-1) from 25 oC to 30 oC 204 
above the expected melting point at a heating rate of 10 oC min-1.  205 
2.2.5.5. Thermogravimetric analysis 206 
Thermogravimetric analysis (TGA) was used for determining the residual 207 
moisture content of the spray-dried formulations. TGA was performed with a 208 
Discovery TGA (TA Instruments, USA) controlled by TRIOS (TA) software. 209 
Weighted powder samples (1-5 mg) were placed into aluminium cups (TA) and 210 
heated under nitrogen flow (50 mL min-1) from 25 to 120 oC at a heating rate of 211 
10 oC min-1. The residual moisture content was calculated as the weight loss 212 
between 25 and 120 o C. 213 
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2.2.5.6. Drug loading  214 
5 mg of nanoparticle agglomerates were dissolved in 50 mL methanol, and 215 
ibuprofen concentration was assayed using an HPLC system (Agilent 1100 Series, 216 
Agilent technologies, Germany). The stationary phase was a Luna® (150 x 4.60 217 
mm, 5 micron) column (Phenomenex Co., California, USA) kept at 30 o C. The 218 
mobile phase comprised acetonitrile and aqueous trifluoroacetic acid solution 219 
(0.1% v/v) at 50/50 volumetric ratio. The mobile phase flow rate was 1 mL min-1, 220 
the injection volume was 10 μL and the detection wavelength 214 nm. The 221 
retention time for ibuprofen was 7.4 min. The correlation coefficient of the 222 
calibration curve was R2=0.9999 for a concentration range of 5-600 μg mL-1, 223 
indicating acceptable linearity. 224 
2.2.5.6. Redispersibility  225 
Redispersibility index (RDI%) was determined according to Yue et al. [13]: 226 
. 227 
where, z-average0 is the intensity-weighted mean particle diameter of the 228 
nanosuspensions prior to spray drying measured by DLS and z-average is the 229 
corresponding value of nanosuspension reconstituted from nanoparticle 230 
agglomerates upon rehydration. For the measurement of redispersibility, around 231 
100 mg of each spray-dried powder was added to a glass vial containing 10 mL of 232 
an aqueous saturated IBU solution and it was shaken vigorously for 30s by hand 233 
before being transferred to disposable sizing cuvettes.  The saturated solution of 234 
ibuprofen was prepared by filtration of a drug suspension through a 0.1 μm 235 
disposable syringe filter in order to avoid extensive dissolution. A RDI value close 236 
to 100% indicates that the spray-dried nanoparticle agglomerates exhibit complete 237 
reconstitution after rehydration to particles of similar size as the primary 238 
nanocrystals after nanomilling and before the solidification step.  239 
2.2.5.7. In-vitro dissolution testing 240 
The paddle method was applied by using USP apparatus type II (Pharma Test, 241 
Germany), at 37 oC and 50 rpm stirring speed. The dissolution medium was 500 242 
mL of deionised water (freshly boiled and cooled, pH: 6-7). At specific time 243 
100*%
0averagez
averagez
RDI



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intervals up to 120 min, 5 mL of dissolution medium was withdrawn, filtered 244 
through a 0.1 μm disposable syringe filter and placed in HPLC vials for assay, 245 
whilst being immediately replaced with 5 mL of fresh medium. The HPLC 246 
conditions for the assay were as for drug content determination. Dissolution tests 247 
were conducted in triplicate for each formulation.  248 
 249 
2.2.5.8. In-vitro aerosol performance 250 
The aerodynamic assessment of the nanoparticle agglomerates was carried out 251 
using the fast screening impactor, FSI (MSP 185 FSI, Copley Scientific, UK). The 252 
FSI was developed based on the abbreviated impactor measurement concept. It 253 
divides the particles discharged from the inhaler into two parts: the coarse fraction 254 
and the fine fraction (aerodynamic diameter less than 5 μm). The coarse fraction 255 
collector was equipped with an insert that enables a cut-off of 5 μm at 30 L min-1. 256 
The particles not captured in the coarse fine collector followed the airstream and 257 
deposited in the fine fraction collector where a filter captured all of them. The FSI 258 
was connected to a high-capacity vacuum pump (Model HCP5, Copley 259 
Instruments, UK). Based on results from preliminary studies the bottom plate of 260 
the pre-separator was coated with 1% w/v silicone oil in hexane in order to reduce 261 
particle bounce that is created from the additional 5 μm cut-off plate. The actual 262 
flow rate was measured using a calibrated flow meter (Flow Meter Model DFM 263 
2000, Copley Instrument Ltd, UK) prior to each run, to ensure that a flow at 30 L 264 
min-1 was achieved. Gelatin hard capsules (size 3) were filled with accurately 265 
weighed amounts of product (ranging from 12.5 to 28 mg depending on the drug 266 
loading of each formulation) corresponding to about 10 mg of IBU. The capsules 267 
were placed in the inhaler device (Cyclohaler®) fitted to the impactor via an 268 
airtight rubber adaptor and tested at 30 L min-1 for 8 s (total volume: 4 L).  The 269 
capsules were discharged into the FSI and after dispersion the particles were 270 
collected on a glass fiber filter (76 mm, Pall Corporation, USA) and extracted in 271 
methanol. Analysis of the extracts from the capsules, mouthpiece and each part of 272 
the FSI was performed with HPLC. The HPLC conditions for the assay were as 273 
for drug content determination. Each formulation was tested in triplicate. The fine 274 
particle fraction (FPF%) of the formulations was the ratio of the drug mass 275 
depositing on the fine fraction collector divided by the recovered dose. The fine 276 
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particle dose (FPD) was calculated as the total mass deposited on the fine fraction 277 
collector divided by the number of doses (n=3).  278 
 279 
2.2.5.9. Design of Experiments 280 
A full factorial design 23 (3 factors at 2 levels) was used allowing the estimation 281 
of the main effects and the two-way interactions. The three independent variables 282 
used at two levels in the design were: type of stabilizer (X1), mannitol to drug ratio 283 
(X2) and leucine to drug ratio (X3). Dependent variables: yield, volume median 284 
diameter (D50), redispersibility index (RDI%) and fine particle fraction (FPF%), 285 
were selected as responses (Table 1). The design matrix included 8 runs plus four 286 
centre points (Fig. 1). Centre points were added to the design space to identify any 287 
non-linearity in the responses. The design space was constructed and analyzed 288 
using the JMP 12.1.0 software (SAS Institute, USA). To reduce systematic errors, 289 
all the experiments were completely randomized. The standard least squares model 290 
(including multiple linear regression analysis and ANOVA) was fitted in to model 291 
the data. The significance and validity of the model was estimated by ANOVA. 292 
The parameter estimates and the probability values (p-values) of the effects and 293 
two-way interactions of each response are given. p-values less than 0.05 were 294 
deemed to be statistically significant. 295 
 296 
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3. Results and discussion 297 
3.1. Preparation and characterization of nanosuspensions 298 
Both stabilizers were able to produce nanosuspensions of ibuprofen after 180 min 299 
of wet milling. The results of z-average size and polydispersity index (PI) of 300 
nanosuspensions obtained with both stabilizers as a function of milling time are 301 
presented in (Fig. 2). More specifically, after 180 min nanosuspensions stabilized 302 
with HPMC and TPGS exhibited a z-average size of 533 ± 28 nm and 663 ± 12 303 
nm, respectively.  304 
 305 
The starting material, with a volume mean diameter D4,3: 64.5 ± 8.3 μm (Fig. 3) 306 
initially showed rapid size reduction during milling, especially with HPMC as 307 
stabilizer. In the case of HPMC, submicron particles of ibuprofen were produced 308 
in 60 min while for TPGS this occurred in 90 min. The breakage rate of crystals 309 
was high initially and with further milling time the size continued to decrease, but 310 
at a slower rate for both stabilizers. This is a common profile as breakage rate 311 
kinetics have been found to follow a first-order exponential decay [35].  312 
 313 
In the study of Nihei et al. [27], thymoquinone, a low melting compound (m.p. 46 314 
oC) with antioxidant properties had to be nanosized using a cold wet-milling 315 
system in order to avoid the formation of large aggregates that were caused by the 316 
partial melting of the compound when a wet mill without a heat exchanger was 317 
used. In this study, no aggregation of ibuprofen was observed during milling 318 
indicating that cautious selection of the process parameters (i.e. a lower milling 319 
speed and an increased milling time with intervals so as to cool down the vessels) 320 
could allow the use of wet mills which are not equipped with temperature control 321 
accessories for the nano-comminution of low melting drugs. This could be 322 
especially applicable to preformulation research at preclinical and clinical studies 323 
were limited resources are available (i.e. time, equipment, investment, compound).  324 
 325 
The results reported in this study can be favorably compared with those obtained 326 
by rapid expansion of supercritical solutions [36] and high pressure 327 
homogenization [37], as both methods could not produce ibuprofen crystals with 328 
size in the submicrometre scale.   329 
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 330 
Comminution of ibuprofen in water using a Lena DM 100 nanoparticle production 331 
machine, equipped with a heat exchanger and operating in the recirculation mode, 332 
resulted in nanosuspensions with z-average size around 450 nm [38]. The smaller 333 
size of nanocrystals reported may be attributed to the use of a combination of 334 
polymers and surfactants as stabilizers, and this also indicates the scalability of 335 
wet milling in industrial settings [39].  336 
 337 
3.2. Yield 338 
The yield was selected as a response characterizing quantitatively the overall 339 
productivity of the process. For the experimental conditions applied the yield 340 
ranged from 27.3% to 72.5% (Table 1). The generated model was significant and 341 
the response was modeled with high accuracy (adjusted R2: 0.96, Table 2). 342 
 343 
All the three independent variables were identified as significant with a positive 344 
effect on the yield of the process (p<0.05, Table 2). The positive effect of 345 
increasing the leucine and mannitol to drug ratios may be attributed to the 346 
increased concentration of the solids dissolved in the feed suspension, prior to the 347 
spray-drying step. Spray drying of nanosuspensions stabilized with TPGS led to 348 
the lowest yield of 27.3%. This low yield may be attributed to the low melting 349 
point of TPGS resulting in melting and adhesion of the nanoparticle agglomerates 350 
to the drying chamber and cyclone. Replacing TPGS with HPMC, which is a non-351 
thermolabile stabilizer increased the yield. The yield of the process was found to 352 
maximize by increasing the leucine to drug ratio. This may be explained by the 353 
fact that leucine accumulates on the surface of the particles forming a coating 354 
around them and thus protecting them from high temperatures during spray drying. 355 
Similar results were reported regarding the spray drying of hydro-alcoholic 356 
solutions of β-estradiol where the powder yield increased with increasing leucine 357 
content in the formulation [40]. The explanation proposed by the authors was that 358 
when increasing leucine content was used, the drug was encapsulated in micelle-359 
like structures of leucine and thus was protected from the relative harsh spray-360 
drying conditions.  361 
As shown in the surface plots (Fig. 6a,b) higher yields are obtained when HPMC 362 
was used as the stabilizer of ibuprofen nanosuspensions, and when high leucine 363 
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and mannitol to drug ratios were used in the formulations prior to the spray-drying 364 
step. 365 
 366 
3.3. Characterization of nanoparticle agglomerates  367 
3.3.1. Particle size and morphology 368 
The SEM images of the formulations prepared based on the full factorial design 369 
are shown in Fig. 4,5. Spray drying of ibuprofen nanosuspensions stabilized either 370 
by HPMC or TPGS in the absence of excipients resulted in aggregated particles of 371 
irregular morphology with size outside the acceptable range for pulmonary drug 372 
delivery (Table 1 and Fig.4,5). 373 
 374 
Addition of mannitol and/or leucine resulted in the promotion of spherical particles 375 
with mean size approximately 2-3 μm that is suitable for pulmonary drug delivery. 376 
The surface of the spray-dried particles appears not to be smooth and a closer 377 
inspection reveals the presence of nanoparticles indicating the composite structure 378 
of the particles where ibuprofen nanocrystals are embedded in a matrix of mannitol 379 
and/or leucine (i.e. nanoparticle agglomerates).  380 
 381 
The nanoparticle agglomerates containing leucine consist of individual particles 382 
(e.g. patterns 1-+, 2-+, Fig.4,5). This may be attributed to the accumulation of 383 
leucine at the surface of the particles preventing any particle fusion. A high leucine 384 
to drug ratio resulted in wrinkled particles (patterns 1++, 2++, Fig.4,5). A wrinkled 385 
morphology was interpreted as an indication of hollow particles as the particle 386 
density was found to decrease as the “wrinkleness” of the particles was increased 387 
[41]. 388 
 389 
The nanoparticle agglomerates appear to be porous with holes and dimples in the 390 
particle surface due to the evaporation of liquid that escapes from the inner of the 391 
droplet through the solid crust built up in the course of the drying process on the 392 
surface of the droplet [15,42]. Engineering of porous particles is considered 393 
beneficial for pulmonary drug delivery as particles with high porosity have smaller 394 
aerodynamic diameter compared to non-porous particles of the same physical size, 395 
increasing the probability for deposition in the lower respiratory tract [43]. 396 
 397 
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The particle size of the nanoparticle agglomerates obtained was measured by laser 398 
diffraction as a volume diameter (Table 1). The dried powders obtained exhibited 399 
a median diameter D50 between 2.15 and 16.04 μm and the data are in good 400 
agreement with the particle size observed by SEM. The results were analyzed in 401 
the experimental design performing ANOVA for particle size, focusing on the D50 402 
value and the model was found significant (p<0.05, Table 2).  403 
 404 
Leucine to drug ratio and the type of stabilizer used were identified as formulation 405 
variables with the most significant effects on the D50 (Table 2). Their “negative” 406 
effect is interpreted as size reduction, which is desirable for pulmonary drug 407 
delivery. The observation regarding the influence of leucine on particle size is in 408 
agreement with the study of Sou et al. [20] in which it was reported that leucine in 409 
contrast to glycine and alanine was the only amino acid that reduced the D50 when 410 
added into the mannitol formulations. Also, it is likely that increased leucine to 411 
drug ratio enhanced surface coating around the particles, which prevented the 412 
particles from melting and sintering, as observed for the process yield.  413 
 414 
A significant interaction was identified between leucine to drug ratio and the type 415 
of stabilizer, with a positive parameter estimate, despite the fact that the factors 416 
had individually negative effects on the D50 (Table 2), indicating a synergistic 417 
rather than an additive interaction between HPMC and leucine to drug ratio. Use 418 
of the non-melting HPMC as a nanosuspension stabilizer and the addition of a high 419 
leucine to drug ratio leads to further particle size reduction than the individual 420 
factors alone. 421 
As shown in the surface plot, spray drying of ibuprofen nanosuspensions stabilized 422 
with HPMC and containing a high leucine to drug ratio is able to produce 423 
nanoparticle agglomerates with particle size around 2-3 μm that is suitable for 424 
pulmonary drug delivery (Fig. 6c). On the other hand, spray drying of ibuprofen 425 
nanosuspensions stabilized with TPGS results in larger particles, while addition of 426 
both high leucine and mannitol to drug ratios was required in order to produce 427 
particles smaller than 4 μm (Fig. 6d). This indicates that the selection of stabilizer 428 
is vital not only for the step of nanosuspension production, but it may also 429 
 17 
 
influence the downstream process of spray drying by affecting the properties of 430 
the nanoparticle agglomerates produced. 431 
3.3.2. Redispersibility  432 
Redispersibility is an important quality attribute of nanoparticle agglomerates as 433 
it is a prerequisite for the reformation of nanoparticles upon rehydration of the 434 
larger particles with potential enhancement of therapeutic efficacy. Particularly, 435 
for nanoparticles of low melting drugs such as ibuprofen, thermal stresses during 436 
spray drying may lead to phase and composition changes of formulations causing 437 
irreversible aggregation and loss of the advantages of nanoformulations [12]. An 438 
RDI% value close to 100% means that the nanoparticle agglomerates reformed 439 
nanoparticles with z-average size close to the z-average size of the primary 440 
nanoparticles prior to the solidification step. For the experimental conditions 441 
applied, the redispersibility index (RDI%) ranged from 148 % to 938% (Table 1). 442 
The redispersibility results were analyzed in the experimental design performing 443 
ANOVA for particle size focusing on the RDI% value and the model was found 444 
significant (p<0.05, Table 2). 445 
 446 
The mannitol to drug ratio was identified as the only significant factor affecting 447 
redispersibility (p<0.05, Table 2) with higher mannitol to drug ratio leading to 448 
RDI% values closer to 100%. The role of mannitol as a redispersibility enhancer 449 
can be explained by the formation of a continuous matrix around the nanocrystals 450 
during the spray-drying step, preventing their irreversible aggregation. Upon 451 
rehydration, mannitol as a hydrophilic excipient dissolves and the 452 
nanosuspensions are reconstituted. 453 
 454 
As shown in the surface plots (Fig. 7a,b), nanoparticle agglomerates of ibuprofen 455 
with enhanced redispersibility (RDI% value close to 100%) were obtained only 456 
when high mannitol to drug ratios are present in the formulations prior to the spray-457 
drying step. 458 
3.3.3. Drug loading  459 
The results of assayed ibuprofen content in the nanoparticle agglomerates are 460 
given in Table 3. Spray drying of nanosuspensions without mannitol and/or leucine 461 
appeared to have lower drug loading than the nominal. This may be attributed to 462 
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the melting of TPGS during spray drying that led to drug loss due to deposition on 463 
the walls of the drying chamber and cyclone. For the spray-dried nanosuspensions 464 
containing mannitol and/or L-leucine the assayed ibuprofen content is close to the 465 
nominal content indicating that the addition of these excipients prevented 466 
ibuprofen loss or powder segregation during the production process.  467 
 468 
3.3.4. Solid state characterization  469 
The XRPD patterns of the starting materials are shown in Fig.8a. Raw ibuprofen 470 
exhibited sharp peaks in the range of 2 theta: 15-25 o that are characteristic of the 471 
drug [38,44]. Mannitol starting material exhibited characteristic peaks of the β-472 
form  (2 theta: 10.6o, 14.7o, 16.9o, 21.2o, 23.9o, 29.5o) [45] while the diffractogram 473 
of L-leucine indicated a highly crystalline structure (2 theta: 6o, 12o, 24o, 31o, 37o) 474 
[46].  475 
 476 
The diffractograms of all runs prepared according to the DoE are shown in Fig. 477 
8b. The diffractograms of patterns 1-- and 2-- (without matrix former and 478 
dispersibility enhancer) showed peaks at similar 2 theta positions to those of the 479 
raw ibuprofen. For the nanoparticle agglomerates of ibuprofen containing 480 
mannitol and/or leucine, the diffractograms were a summation of the patterns of 481 
their components. No new peaks or halo could be detected in the XRPD patterns 482 
indicating the absence of generated amorphous content during the process. 483 
 484 
The DSC was used to assess the thermal behaviour of the starting materials and 485 
nanoparticle agglomerates of ibuprofen (Fig. 9). The DSC thermogram of 486 
ibuprofen showed an endothermic peak at 76 oC corresponding to the melting of 487 
the drug. The nanoparticle agglomerates of ibuprofen without mannitol and 488 
leucine exhibited the same endothermic peak shifted to a slightly lower 489 
temperature (Fig. 9a), while those containing mannitol exhibited thermal 490 
behaviour depending on the stabilizer.  491 
 492 
More specifically, the nanoparticle agglomerates of ibuprofen containing mannitol 493 
and stabilized with TPGS exhibited two endothermic peaks (patterns 2++, 2+-, 494 
Fig. 9b) as expected: the melting peak at around 70 o C, which relates to the melting 495 
of the drug and a sharp endothermic peak at 168 oC which relates to the melting of 496 
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mannitol (Pearlitol: 160 oC). For the nanoparticle agglomerates of ibuprofen 497 
containing mannitol and stabilized with HPMC, apart from the melting of 498 
ibuprofen, an endothermic peak at 150 oC was followed by an exothermic event 499 
and then an endothermic melting at 168 oC (patterns 1++, 1+-, Fig. 9b). The 500 
thermal events observed in the DSC of patterns 1++ and 1+- could be attributed to 501 
the formation of the metastable δ-form of mannitol (m.p. 150-158 oC) that is 502 
followed by crystallization to the α- or/and β-form, and the melting of the 503 
respective crystal form [47]. Both α- and δ-form of mannitol were found to be 504 
chemically and physically stable for at least 5 years when stored at 25 oC and 43% 505 
relative humidity [47]. Recently, co-spray drying of an aqueous solution of 506 
mannitol with PVP in a ratio 4:1 was reported to produce the δ-form of mannitol 507 
[48]. 508 
 509 
Overall, the XRPD and DSC data suggest that the engineered nanoparticle 510 
agglomerates retain their crystallinity during wet bead milling followed by spray 511 
drying. The preservation of the crystalline state is advantageous, ensuring the long-512 
term physical stability of the formulations during storage.  513 
 514 
3.3.5. Residual moisture content 515 
Thermogravimetric analysis of the spray-dried powders indicated that the moisture 516 
content of the powders ranged from 1.1 to 4.7% w/w (Table 3). These values 517 
compare favourably with other studies which report moisture content of spray-518 
dried powders in the region of 5-10% w/w [49,50]. Specifically, residual moisture 519 
content ranged from 2.3 to 4.7% for the nanoparticle agglomerates stabilized with 520 
HPMC and from 1.1 to 2.3% for those stabilized with TPGS and it was reduced 521 
for the agglomerates with high mannitol to drug ratio (Table 3). This is in 522 
agreement with the results reported by Yamasaki et al. [7], that increasing mannitol 523 
content in nanomatrix powders of ciclosporin A reduced the residual moisture 524 
content of the formulations, which was attributed to its non-hygroscopic nature. 525 
Thus, despite the low inlet (70 oC) and outlet temperature (50 oC), selected to 526 
prevent melting of the drug during spray drying, addition of mannitol can 527 
minimize the moisture content of the nanoparticle agglomerates that is required 528 
for quality reasons (e.g. physical and chemical stability, reduced cohesiveness 529 
during storage, non-aggregation) [51].  530 
 20 
 
3.3.6. In-vitro dissolution tests 531 
The dissolution profiles of ibuprofen and the nanoparticle agglomerates prepared 532 
according to the matrix of the full factorial design are shown in Fig. 10. 533 
Nanoparticle agglomerates stabilized with either HPMC or TPGS exhibited 534 
enhanced dissolution profiles compared to ibuprofen. In the case of the raw 535 
ibuprofen, less than 40% was released in the first 20 min, while the nanoparticle 536 
agglomerates achieved complete dissolution in less than 5 min. The exceptions to 537 
this were the spray-dried nanosuspensions of ibuprofen without matrix former 538 
(patterns 1-- and 2--) which exhibited a higher dissolution rate compared to 539 
ibuprofen but slower than the nanoparticle agglomerates containing mannitol 540 
and/or leucine. In the case of TPGS, this may be associated with the formation of 541 
large aggregates with size around 50 μm and poor redispersibility (Fig. 5). Thus, 542 
the selection of suitable process and formulation parameters is of paramount 543 
importance in order to ensure that the dissolution benefit of nanoparticles is 544 
retained after spray drying. 545 
 546 
3.3.7. In-vitro aerosol performance 547 
Fine particle fraction (FPF) was selected as a quality attribute describing the 548 
aerodynamic performance of a dry powder for inhalation. The European 549 
Pharmacopoeia (2.9.18 preparations for inhalation: aerodynamic assessment of 550 
fine particles, Ph. Eur. 8.0) suggest that a pressure drop over the inhaler of 4 kPa 551 
is broadly representative of the pressure drop generated by the patients using dry 552 
powder inhalers during inhalation [52]. In this study, operating a ‘medium’ 553 
resistance device as Cyclohaler® at 30 L min-1 leads to a low pressure drop across 554 
the inhaler. While this low pressure drop across the inhaler reduces the probability 555 
of establishing comparable in-vitro performance and in-vivo drug deposition, it is 556 
considered acceptable for comparing the in-vitro aerosolisation performance of 557 
formulations prepared in this study. The FPF values of the nanoparticle 558 
agglomerates produced ranged from 5.84 to 68.55% (Table 1) and the model 559 
generated was found to be significant (p<0.05, Table 2).  560 
 561 
Leucine to drug ratio and mannitol to drug ratio were identified as the most 562 
significant factors on the FPF (Table 2.). The positive effect of leucine can be 563 
linked with its properties as a dispersibility and aerosolization enhancer. In 564 
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contrast to other amino acids such as alanine and glycine, leucine has been found 565 
to reduce capsule retention and increase both the emitted and the fine particle 566 
fraction of formulations [20,22]. For spray-dried particles of salbutamol sulfate 567 
and lactose containing increasing amount of leucine (5-20% w/w), Seville et al 568 
[22] observed an increase of the FPF% (from 50% to 80%, respectively). In 569 
another study, Sou et al. [20] reported the highly significant and positive effect of 570 
leucine on improving the FPF% of spray-dried mannitol particles.  571 
 572 
 573 
Regarding the positive effect of mannitol to drug ratio, it may be attributed to the 574 
good spray-drying properties of mannitol which facilitates the formation of 575 
spherical particles with narrow and unimodal particle size distribution [15,53]. 576 
 577 
As illustrated in the surface plots (Fig. 7c, d), both leucine and mannitol to drug 578 
ratio have a significant effect on the aerodynamic performance of the nanoparticle 579 
agglomerates, resulting in a large FPF increase from 10% to over 65%. Therefore, 580 
a combination of high leucine and mannitol to drug ratios is required in order to 581 
maximise the FPF of the nanoparticle agglomerates of the low melting and ductile 582 
ibuprofen. 583 
 584 
4. Conclusions 585 
Nanosuspensions of the poorly water-soluble, low melting point and ductile drug 586 
ibuprofen stabilized with HPMC and TPGS were successfully produced and were 587 
further spray dried with or without the addition of excipients (mannitol and/or L-588 
leucine) employing a full factorial design. Design of experiments is a useful 589 
approach in order to gain insight into the formation of inhalable nanoparticle 590 
agglomerates using wet milling followed by spray drying. Leucine to drug ratio, 591 
mannitol to drug ratio and the type of stabilizer were found to be significant 592 
(p<0.05) factors affecting the yield of the particles obtained by combining wet 593 
milling and spray drying. The particle size response was mainly dependent on the 594 
leucine to drug ratio and the type of stabilizer employed (p<0.05). Mannitol to 595 
drug ratio was found to be the only critical parameter affecting redispersibility of 596 
nanoparticle agglomerates (p<0.05), and both leucine to drug ratio and mannitol 597 
to drug ratio were found to be significant factors affecting FPF (p<0.05). While 598 
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the importance of the type of stabilizer on the formation of nanosuspensions has 599 
been previously reported [33,54,55], in this study it was observed that the selection 600 
of stabilizer could also influence the downstream process of spray drying by 601 
affecting the yield and the particle size distribution of the resultant nanoparticle 602 
agglomerates. Moreover, the nanoparticle agglomerates were found to be 603 
crystalline which is advantageous for their physical stability upon storage, and they 604 
exhibit enhanced dissolution compared to the ibuprofen starting material. Overall, 605 
it appears that by selecting the stabilizer and adjusting the mannitol and leucine to 606 
drug ratio during the spray drying of nanosuspensions can result in nanoparticle 607 
agglomerates with enhanced dissolution and aerosolization behaviour despite the 608 
challenging properties (thermal and mechanical) of a drug as ibuprofen.  609 
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Tables 
 
Table 1 Matrix of full factorial design, yield of process and characteristics of 
spray-dried nanoparticle agglomerates: volume diameter, redispersibility (RDI %), 
fine particle fraction (FPF%) and fine particle dose (FPD). 
 
Table 2 Summary of the regression analysis and ANOVA results.  
 
Table 3 Nominal content and assayed ibuprofen content (% w/w) of nanoparticle 
agglomerates together with calculated drug loading efficiency (%) and 
residual moisture content (mean ± SD, n=3). 
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Table 1 Matrix of full factorial design, yield of process and characteristics of spray-dried nanoparticle agglomerates: volume diameter, 
redispersibility (RDI %), fine particle fraction (FPF%) and fine particle dose (FPD).  
Formulation 
number 
Pattern Stabiliser Mannitol 
to drug 
ratio 
Leucine 
to drug 
ratio 
Yield 
(%) 
Volume diameter (μm) RDI 
(%) 
FPF 
(%) 
FPD 
(mg) 
      D10 D50 D90    
1 
100 HPMC 0.5 0.25 
58.2 0.92 ± 0.02 3.02 ± 0.04 7.02 ± 0.23 420 58.20 ± 4.2 5.41 ± 0.6 
2 200 TPGS 0.5 0.25 46.6 0.85 ± 0.01 6.20 ± 0.05 9.02 ± 0.13 250 46.62± 5.6 4.42 ± 0.7 
3 1++ HPMC 1 0.5 72.5 0.85 ± 0.00 3.57 ± 0.03 6.82 ± 0.07 283 68.55 ± 3.8 6.23 ± 0.6 
4 100 HPMC 0.5 0.25 56.4 0.83 ± 0.01 2.27 ± 0.01 6.23 ± 0.16 400 45.11 ± 6.1 4.03 ± 0.6  
5 2+− TPGS 1 0 41.1 1.13 ± 0.05 9.88 ± 0.39 24.39 ± 2.70 181 9.32 ± 2.5 0.79 ± 0.3  
6 1−+ HPMC 0 0.5 60.1 0.99 ± 0.02 2.30 ± 0.08 3.83 ± 0.11 751 22.93 ± 1.2 2.11 ± 0.2 
7 2−− TPGS 0 0 27.3 1.56 ± 0.04 16.04 ± 0.33 53.22 ± 
1.51 
765 6.68 ± 2.7 0.58 ± 0.2  
8 2−+ TPGS 0 0.5 53.8 0.88 ± 0.02 2.15 ± 0.02 3.81 ± 0.01 600 40.00 ± 2.3 3.66 ± 0.2  
9 1+− HPMC 1 0 47.9 1.02 ± 0.06 3.22 ± 0.04 5.92 ± 0.34 307 29.56 ± 3.4 2.61 ± 0.5  
10 2++ TPGS 1 0.5 60.0 0.77 ± 0.01 2.23 ± 0.04 6.21 ± 0.01 148 43.63 ± 4.1 4.23 ± 0.6 
11 200 TPGS 0.5 0.25 43.2 0.87 ± 0.01 5.20 ± 0.04 7.31 ± 0.30 280 40.23 ± 2.7 3.64 ± 0.4 
12 1−− HPMC 0 0 37.7 0.96 ± 0.03 4.29 ± 0.09 6.87 ± 1.01 938 5.84 ± 2.8 0.46 ± 0.2  
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Table 2 Summary of the regression analysis and ANOVA results. 
Term Yield D50 (μm) RDI (%) FPF (%) 
 Estimate Std 
Error 
p-value Estimate Std 
Error 
p-value Estimate Std 
Error 
p-value 
 
Estimate Std 
Error 
p-value 
Intercept 50.4 0.71 <0.0001 5.03 0.37 <0.0001 443.59 33.74 <0.0001 31.27 2.57 <0.0001 
Main effects             
X1: Stabiliser 5.07 0.71 0.0008*** -1.92 0.37 0.0033** 72.93 33.74 0.0830 2.73 2.57 0.3366 
X2: Mannitol to 
drug ratio 
5.33 0.87 0.0017*** -0.74 0.45 0.1617 -266.89 41.32 0.0013** 9.45 3.14 0.0298* 
X3: Leucine to 
drug ratio 
11.55 0.87 <0.0001*** -2.90 0.45 0.0013** -51.14 41.31 0.2708 15.48 3.14 0.0044** 
Two-way interactions           
X1*X2 0.33 0.87 0.7231 0.79 0.45 0.1400 -7.89 41.31 0.8561 7.87 3.14 0.0543 
X1*X3 0.2 0.87 0.8267 2.49 0.45 0.0026** -1.64 41.31 0.9699 -1.44 3.14 0.6649 
X2*X3 -0.68 0.87 0.4714 1.07 0.45 0.0620 32.89 41.31 0.4129 2.84 3.14 0.4071 
ANOVA 
 
           
Model   0.0004***   0.0028**   0.0181***   0.0251* 
R2 0.98   0.96   0.91   0.89   
Adj R2 0.96   0.91   0.80   0.76   
* p< 0.05, ** p< 0.01, *** p< 0.001 
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Table 3 Nominal content and assayed ibuprofen content (% w/w) of nanoparticle 
agglomerates together with calculated drug loading efficiency (%) and residual 
moisture content (mean ± SD, n=3). 
Pattern Content (% w/w) 
Drug 
Loading 
Efficiency 
(%) 
Residual 
Moisture 
Content 
(%) 
 Nominal 
Assayed 
IBU  IBU STAB MAN LEU 
100 54.05 5.41 27.03 13.51 50.8 ± 1.3 94.0 ± 2.4 3.5 ± 0.5 
200 54.05 5.41 27.03 13.51 51.8 ± 1.7 95.9 ± 3.2  1.1 ± 0.2 
1++ 38.46 3.85 38.46 19.23 36.7 ± 0.2 95.4 ± 0.5 2.3 ± 0.4 
100 54.05 5.41 27.03 13.51 49.2 ± 1.3 91.0 ± 2.6 3.0 ± 0.4 
2+- 47.6 4.76 47.6 - 44.4 ± 0.8 93.2 ± 1.7 1.6 ± 0.1  
1-+ 62.5 6.25 - 31.25 59.4 ± 1.2 95.0 ± 1.8 3.4 ± 0.5 
2-- 91 9 - - 77.4 ± 1.4 85.1 ± 1.6 2.3 ± 0.5 
2-+ 62.5 6.25 - 31.25 58.3 ± 1.1 93.3 ± 2.1 1.9 ± 0.1 
1+- 47.6 4.76 47.6 - 42.1 ± 2.1 88.5 ± 3.6 2.7 ± 0.2 
2++ 38.46 3.85 38.46 19.23 35.4 ± 0.7 92.0 ± 1.9 1.6 ± 0.3 
200 54.05 5.41 27.03 13.51 50.4 ± 2.1 93.2 ± 3.5 1.3 ± 0.3 
1-- 91 9 - - 80.3 ± 1.9 88.2 ± 2.6 4.7 ± 0.4  
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Figures 
 
Figure 1 The three-dimensional design space of the 23 full factorial design. 
 
Figure 2 z-average size and polydispersity index (PI) of ibuprofen 
nanosuspensions with increasing wet-milling time (mean + SD, n=3). 
 
Figure 3 SEM image of ibuprofen starting material. 
 
Figure 4 SEM images of ibuprofen nanoparticle agglomerates included in the full 
factorial design. The stabiliser is HPMC. 
 
Figure 5 SEM images of ibuprofen nanoparticle agglomerates included in the full 
factorial design. The stabiliser is TPGS. 
 
Figure 6 Surface plots indicating the effect of mannitol to drug ratio and leucine 
to drug ratio on the yield and D50 particle size of the nanoparticle agglomerates 
stabilised with HPMC (a,c) and TPGS (b,d). The arrows indicate the direction of 
increasing values of the variables. 
 
Figure 7 Surface plots indicating the effect of mannitol to drug ratio and leucine 
to drug ratio on the redispersibility and the FPF% of the nanoparticle agglomerates 
stabilised with HPMC (a,c) and TPGS (b,d). The arrows indicate the direction of 
increasing values of the variables.  
 
Figure 8 XRPD diffractograms of (a) starting materials and (b) nanoparticle 
agglomerates included in the full factorial design. 
 
Figure 9 DSC thermograms of (a) ibuprofen and mannitol starting materials and 
(b) nanoparticle agglomerates included in the full factorial design. A magnified 
thermogram between 130 oC and 170 oC, for the pattern 1++, is given in the insert. 
 
Figure 10 Dissolution profiles of ibuprofen starting material and nanoparticle 
agglomerates included in the full factorial design (mean + SD, n=3). The stabiliser 
is (a) HPMC and (b) TPGS. 
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Figure 1 The three-dimensional design space of the 23 full factorial design.
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Figure 2 z-average size and polydispersity index (PI) of ibuprofen 
nanosuspensions with increasing wet-milling time (mean + SD, n=3). 
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Figure 3 SEM image of ibuprofen starting material.
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Figure 4 SEM images of ibuprofen nanoparticle agglomerates included in the full 
factorial design. The stabiliser is HPMC. 
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Figure 5 SEM images of ibuprofen nanoparticle agglomerates included in the full 
factorial design. The stabiliser is TPGS. 
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Figure 6 Surface plots indicating the effect of mannitol to drug ratio and leucine to drug ratio on the yield and D50 particle size of the nanoparticle agglomerates 
stabilised with HPMC (a,c) and TPGS (b,d). The arrows indicate the direction of increasing values of the variables.  
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Figure 7 Surface plots indicating the effect of mannitol to drug ratio and leucine to drug ratio on the redispersibility and the FPF% of the nanoparticle agglomerates 
stabilised with HPMC (a,c) and TPGS (b,d). The arrows indicate the direction of increasing values of the variables.  
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Figure 8 XRPD diffractograms of (a) starting materials and (b) nanoparticle 
agglomerates included in the full factorial design. 
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Figure 9 DSC thermograms of (a) ibuprofen and mannitol starting materials and 
(b) nanoparticle agglomerates included in the full factorial design. A magnified 
thermogram between 130 oC and 170 oC, for the pattern 1++, is given in the insert. 
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 1 
Figure 10 Dissolution profiles of ibuprofen starting material and nanoparticle 2 
agglomerates included in the full factorial design (mean + SD, n=3). The stabiliser 3 
is (a) HPMC and (b) TPGS.  4 
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